Guo Xiaochuan, Qin Yanqin, Feng Zhenzhen, Li Haibo, Yang Jingfan, Su Kailin, Mao Ruixiao, Li Jiansheng
Department of Respiratory Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China.
The First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China.
Heliyon. 2024 Aug 3;10(15):e35307. doi: 10.1016/j.heliyon.2024.e35307. eCollection 2024 Aug 15.
The objectives of this study were to define the superiority of icariin and its derivatives' anti-inflammatory activities and to create a reference framework for evaluating preclinical evidence. This method combines machine learning and meta-analysis to identify underlying biological pathways.
Data came from PubMed, Embase, Web of Science, and the Cochrane Library. SYRCLE was used to evaluate the risk of bias in a subset of research. Meta-analysis and detailed subgroup analyses, categorized by species, genders, disease type, dosage, and treatment duration, were performed using R and STATA 15.0 software to derive nuanced insights. Employing R software (version 4.2.3) and the tidymodels package, the analysis focused on constructing a model and selecting features, with TNF-α as the dependent variable. This approach aims to identify significant predictors of drug efficacy. An in-depth literature facilitated the synthesis of anti-inflammatory mechanisms attributed to icariin and its constituent compounds.
Following a meticulous search and selection process, 19 studies, involving 370 and 260 animals were included in the meta-analysis and machine-learning assessment, respectively. The findings revealed that icariin and its derivatives markedly reduced inflammation markers, including TNF-α and IL-1β. Additionally, machine-learning outcomes, with TNF-α as the target variable, indicated enhanced anti-inflammatory effects of icariin across respiratory, urological, neurological, and digestive disease types. These effects were more pronounced at doses exceeding 27.52 mg/kg/day and treatment durations beyond 31.22 days.
Strong anti-inflammatory effects are exhibited by icariiin and its derivatives, which are especially beneficial in the management of digestive, neurological, pulmonary, and urinary conditions. Effective for periods longer than 31.22 days and at dosages more than 27.52 mg/kg/day. Subsequent research will involve more targeted animal experiments and safety assessments to obtain more comprehensive preclinical evidence.
本研究的目的是确定淫羊藿苷及其衍生物抗炎活性的优势,并为评估临床前证据建立一个参考框架。该方法结合机器学习和荟萃分析来识别潜在的生物学途径。
数据来自PubMed、Embase、Web of Science和Cochrane图书馆。使用SYRCLE评估一部分研究中的偏倚风险。使用R和STATA 15.0软件进行荟萃分析和详细的亚组分析,按物种、性别、疾病类型、剂量和治疗持续时间分类,以获得细微的见解。使用R软件(版本4.2.3)和tidymodels包,分析重点是构建模型和选择特征,以肿瘤坏死因子-α(TNF-α)作为因变量。这种方法旨在确定药物疗效的重要预测因素。深入的文献有助于综合淫羊藿苷及其成分化合物的抗炎机制。
经过细致的检索和筛选过程,分别有19项研究(涉及370只和260只动物)纳入了荟萃分析和机器学习评估。结果显示,淫羊藿苷及其衍生物显著降低了包括TNF-α和白细胞介素-1β(IL-1β)在内的炎症标志物。此外,以TNF-α为目标变量的机器学习结果表明,淫羊藿苷在呼吸道、泌尿系统、神经系统和消化系统疾病类型中具有增强的抗炎作用。这些作用在剂量超过27.52毫克/千克/天和治疗持续时间超过31.22天时更为明显。
淫羊藿苷及其衍生物具有强大的抗炎作用,对消化系统、神经系统、肺部和泌尿系统疾病的治疗尤其有益。在治疗时间超过31.22天和剂量超过27.52毫克/千克/天时有效。后续研究将涉及更有针对性的动物实验和安全性评估,以获得更全面的临床前证据。